Samsung Bioepis plans to secure 20 biosimilars in its products and pipeline by 2030 The new pipeline will include dupilumab, guselkumab, ixekizumab, f...
Arthur D. Little’s Blue Shift Institute has published its latest report, AI’s Hidden DependenciesArthur D. Little’s Blue Shift institute has published...